1 results match your criteria: "Belgium jGustave Roussy Cancer Institute[Affiliation]"
Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
Melanoma Res
August 2016
aDepartment of Oncology, Odense University Hospital, Odense C bThe Finsen Laboratory, Rigshospitalet, and Biotech Research and Innovation Centre, University of Copenhagen, København Departments of cOncology dMedicine ePathology, Herlev University Hospital, Herlev fAarhus University Hospital, Aarhus, Denmark gDepartment of Surgical Oncology, Erasmus University Medical Center-Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands hKarolinska Institute, Stockholm, Sweden iEORTC Headquarters, Brussels, Belgium jGustave Roussy Cancer Institute, Villejuif, France.
This study investigates the prognostic and predictive value of YKL-40 in stage IIB-III melanoma patients who were randomized to adjuvant interferon α-2b (IFN) or observation. Serum YKL-40 was determined postoperatively in patients from the Nordic IFN Trial (n=602), EORTC 18952 (n=246), and EORTC 18991 (n=386) (EORTC, European Organisation for Research and Treatment of Cancer). YKL-40 protein expression was determined in 300 tissue sections of primary melanoma or lymph node metastases from 204 Danish patients from the Nordic IFN Trial.
View Article and Find Full Text PDF